Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8119035 | 0.80 | RORC (0.37) | — | |
| SCHEMBL353103 | 0.79 | KLK7 (0.43) | — | |
| SCHEMBL211418 | 0.76 | CHRM2 (0.35) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL4501438 | 0.75 | CHRM2 (0.31) | CHRM2CHRM1CHRM3 | |
| SCHEMBL189841 | 0.74 | SMN1; SMN2 (0.33) | KDM4E | |
| SCHEMBL190827 | 0.73 | NFKB1 (0.30) | — | |
| SCHEMBL6861095 | 0.72 | KLK7 (0.33) | — | |
| SCHEMBL1149816 | 0.70 | RIPK1 (0.38) | BUB1KDM4EMAPT | |
| SCHEMBL8972514 | 0.69 | CHRM2 (0.33) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL1861184 | 0.69 | NR1H2 (0.34) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618152-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120014914-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-19 | — | — | US | disclosed |
| US-20090022688-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-22 | — | — | US | disclosed |
| US-20050090450-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS, INCORPORATED | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014914-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASES | PRSS1, SERPINB1, SPINT2 | BUB1 1866/4885CHRM2 4876/4885CHRM1 4854/4885 |
| US-20050090450-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | PRSS1, SERPINB1, SPINT2 | BUB1 1869/4885CHRM2 4874/4885CHRM1 4848/4885 |
| US-20090022688-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | BUB1 1954/4885CHRM2 4872/4885CHRM1 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.